Evaluation of Efficay & Safety of Galcanezumab in the Prevention of Episodic Migraine- the EVOLVE-2 Study
Clinical trial NCT02614196 · COMPLETED
Trial details
- NCT number
- NCT02614196
- Sponsor
- Eli Lilly and Company
- Status
- COMPLETED
- Phase
- Phase 3
- Study type
- INTERVENTIONAL
- Start date
- 2015-12-04
- Primary completion
- 2017-03-29
- Enrollment
- 986
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.